TY - JOUR
T1 - Laryngeal neuroendocrine carcinoma
T2 - A population-based analysis of incidence and survival
AU - Ghosh, Ritam
AU - Dutta, Rahul
AU - Dubal, Pariket M.
AU - Park, Richard Chan
AU - Baredes, Soly
AU - Eloy, Jean Anderson
N1 - Publisher Copyright: © Official journal of the American Academy of Otolaryngology-Head and Neck Surgery Foundation.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Objective Laryngeal neuroendocrine carcinoma (LNEC) is a rare malignancy with various subtypes, each with different characteristics. Classification of these subtypes is used to delineate treatment and management, as most are clinically aggressive with poor prognosis. This study analyzes the characteristics and survival outcomes of LNEC using population-based data. Study Design Analysis of a population-based tumor registry. Setting Academic medical center. Subjects and Methods The Surveillance, Epidemiology, and End Results (SEER) database (1973-2011) was queried for LNEC cases. Data analyzed included patient demographics, incidence, treatment modality, and survival. Results In total, 257 LNEC cases were extracted from the SEER database. Sixty-three percent were male, and the mean age of diagnosis was 61.9 years. Most cases were located in the supraglottis (62.6%), were of the small cell carcinoma (52.9%) histologic subtype, and were grade IV (40.9%) and American Joint Committee on Cancer (AJCC) stage IV (59.4%). Surgery and radiotherapy were used as treatment modalities in 38.3% and 59.8% of patients, respectively. Overall 5-year disease-specific survival (DSS) for all LNEC was 30.2%, with lower grade, lower AJCC stage, and treatment with surgery having higher 5-year DSS. Conclusions LNEC often presents as an aggressive tumor at an advanced stage and has poor survival outcomes. Poor prognostic factors include high histologic grade, advanced stage disease, and not undergoing surgical resection. LNEC may be best treated depending on its histologic differentiation, with surgery being beneficial for early grade tumors while radiotherapy is inconclusive in its benefit for late-stage disease.
AB - Objective Laryngeal neuroendocrine carcinoma (LNEC) is a rare malignancy with various subtypes, each with different characteristics. Classification of these subtypes is used to delineate treatment and management, as most are clinically aggressive with poor prognosis. This study analyzes the characteristics and survival outcomes of LNEC using population-based data. Study Design Analysis of a population-based tumor registry. Setting Academic medical center. Subjects and Methods The Surveillance, Epidemiology, and End Results (SEER) database (1973-2011) was queried for LNEC cases. Data analyzed included patient demographics, incidence, treatment modality, and survival. Results In total, 257 LNEC cases were extracted from the SEER database. Sixty-three percent were male, and the mean age of diagnosis was 61.9 years. Most cases were located in the supraglottis (62.6%), were of the small cell carcinoma (52.9%) histologic subtype, and were grade IV (40.9%) and American Joint Committee on Cancer (AJCC) stage IV (59.4%). Surgery and radiotherapy were used as treatment modalities in 38.3% and 59.8% of patients, respectively. Overall 5-year disease-specific survival (DSS) for all LNEC was 30.2%, with lower grade, lower AJCC stage, and treatment with surgery having higher 5-year DSS. Conclusions LNEC often presents as an aggressive tumor at an advanced stage and has poor survival outcomes. Poor prognostic factors include high histologic grade, advanced stage disease, and not undergoing surgical resection. LNEC may be best treated depending on its histologic differentiation, with surgery being beneficial for early grade tumors while radiotherapy is inconclusive in its benefit for late-stage disease.
KW - SEER
KW - demographic
KW - disease-specific survival
KW - incidence
KW - laryngeal carcinoma
KW - laryngeal malignancy
KW - laryngeal neuroendocrine carcinoma
KW - malignancy
KW - neuroendocrine carcinoma
KW - throat cancer
UR - http://www.scopus.com/inward/record.url?scp=84948773306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948773306&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/0194599815594386
DO - https://doi.org/10.1177/0194599815594386
M3 - Article
C2 - 26183520
SN - 0194-5998
VL - 153
SP - 966
EP - 972
JO - Otolaryngology - Head and Neck Surgery (United States)
JF - Otolaryngology - Head and Neck Surgery (United States)
IS - 6
ER -